Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 9, 2023

Total Value ($000): $84,298 (100.0% shares, 0.0% debt)

Holdings (8)

— Repare Therapeutics, Inc. 33.2%

Value ($000) $28,002 Shares 2,646,657 Est. Cost $10.58 Unrealized —

CRSP CRISPR Therapeutics AG 33.2%

Value ($000) $27,989 Shares 498,558 Est. Cost $40.26 Unrealized +40.9%

— Adverum Biotechnologies, Inc. 9.6%

Value ($000) $8,058 Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Gritstone Oncology, Inc. 8.2%

Value ($000) $6,944 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— CymaBay Therapeutics, Inc. 7.1%

Value ($000) $5,954 Shares 543,753 Est. Cost $9871.60 Unrealized —

— Passage Bio, Inc. 5.5%

Value ($000) $4,669 Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Aligos Therapeutics, Inc. 2.7%

Value ($000) $2,253 Shares 2,320,381 Est. Cost $27.65 Unrealized —

— Minerva Surgical Inc. 0.5%

Value ($000) $429 Shares 1,673,700 Est. Cost $5.14 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Repare Therapeutics, Inc.	2,646,657	$28,002	33.2%	$10.58	—	Common Stock	760273102
CRSP	CRISPR Therapeutics AG	498,558	$27,989	33.2%	$40.26	+40.9%	Common Shares	H17182108
—	Adverum Biotechnologies, Inc.	5,068,233	$8,058	9.6%	$9646.10	—	Common Stock	00773U108
—	Gritstone Oncology, Inc.	3,561,150	$6,944	8.2%	$7767.86	—	Common Stock	39868T105
—	CymaBay Therapeutics, Inc.	543,753	$5,954	7.1%	$9871.60	—	Common Stock	23257D103
—	Passage Bio, Inc.	4,959,769	$4,669	5.5%	$17.48	—	Common Stock	702712100
—	Aligos Therapeutics, Inc.	2,320,381	$2,253	2.7%	$27.65	—	Common Stock	01626L105
—	Minerva Surgical Inc.	1,673,700	$429	0.5%	$5.14	—	Common Stock	60343F106